Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 1, 2016, Pages

  Gross, Catharina C ^a   Schulte Mecklenbeck, Andreas ^a   Klinsing, Svenja ^a   Posevitz Fejfár, Anita ^a   Wiendl, Heinz ^a   Klotz, Luisa ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 84982187041     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000183     Document Type: Article

References (37)

1. Fox RJ, Philips JT, Hutchinson M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.
2. Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
3. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
4. Schilling S, Goetz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-107.
5. Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-1388.
6. Vandermeeren M, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997;234:19-23.
7. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2) - like 2 pathway. J Pharmacol Exp Ther 2012;341:274-284.
8. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BAC, Zamvil SS. Reduction of CD8 (1) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2015;2:e76. doi: 10.1212/NXI.0000000000000076.
9. Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler 2014;21:796-797.
10. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-1658.
11. van Oosten BW, Killestein J, Barkhof F. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;358:1658-1659.
12. Sweetser MT, Dawson KT, Bozic C. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013;369:1082.
13. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015;372:1476-1478.
14. Posevitz-Fejfár A, Posevitz V, Gross CC, et al. Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking. PLoS One 2014;9:e115920. doi: 10.1371/journal.pone.0115920.
15. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogeninduced human TH17 cells produce IFN-g or IL-10 and are regulated by IL-1b. Nature 2012;484:514-518.
16. Breuer J, Schwab N, Schneider-Hohendorf T, et al. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann Neurol 2014;75:739-758.
17. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp31 T regulatory cells. J Immunol 2010;184:3433-3441.
18. Gasnault J, de Göer de Herve MG, Michot JM, et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect Dis 2014;1:ofu074. doi: 10.1093/ofid/ofu074.
19. Delgado-Alvado M, Sedano MJ, Gonzáles-Quintanilla V, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci 2013;327:75-79.
20. Antoniol C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol 2014;5:668.
21. Lehmann JCU, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007;127:835-845.
22. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097-1102.
23. Neukirch F, Lyon-Caen O, Clanet M, et al. Asthma, nasal allergies, and multiple sclerosis. J Allergy Clin Immunol 1997;99:270-271.
24. Simpson CR, Anderson WJ, Helms PJ, et al. Coincidence of immune-mediated diseases driven by Th1 and Th 2 subsets suggests a common aetiology. A population-based study using computerized general practice data. Clin Exp Allergy 2002;32:37-42.
25. Adorini L, Guéry JC, Trembleau S. Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Autoimmunity 1996;23:53-68.
26. Matusevicius D, Kivisäkk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-104.
27. Schwarz A, Schumacher M, Pfaff D, et al. Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. J Immunol 2013;190:4965-4970.
28. Trinschek B, Luessi F, Haas J, et al. Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoS One 2013;8:e77634. doi: 10.1371/journal.pone.0077634.
29. Schirmrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006;13:604-610.
30. Moed H, Stoof TJ, Boorsma DM, et al. Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles. Clin Exp Allergy 2004;34:1868-1875.
31. Zoghi S, Amirghofran Z, Nikseresht A, et al. Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients with fumaric acid esters. Immunol Invest 2011;40:581-596.
32. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 2008;139:390-395.
33. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 2012;142:44-48.
34. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-692.
35. Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol 2015;130:279-295.
36. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001;116:203-208.
37. Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signalregulated kinase 1 and 2 (ERK1/2) and mitogen stressactivated kinase 1 (MSK1) signaling. J Biol Chem 2012;287:28017-28026.